
Meridian Bioscience VIVO
Quartalsbericht 2022-Q4
hinzugefügt 09.02.2023
Meridian Bioscience Kurzfristige Verbindlichkeiten 2011-2026 | VIVO
Kurzfristige Verbindlichkeiten Jährlich Meridian Bioscience
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 58 M | 47.2 M | 52.5 M | 20.9 M | 24.2 M | 22.9 M | 22.6 M | 15.3 M | 13.7 M | 21.7 M | 18.5 M | 15.3 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 58 M | 13.7 M | 27.7 M |
Kurzfristige Verbindlichkeiten anderer Aktien in der Diagnostik & Forschung
| Name | Kurzfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Agilent Technologies
A
|
1.71 B | $ 115.35 | -2.33 % | $ 35.1 B | ||
|
Anixa Biosciences
ANIX
|
1.97 M | $ 2.81 | -2.7 % | $ 91.2 K | ||
|
Akumin
AKU
|
169 M | - | -17.87 % | $ 25.9 M | ||
|
Check-Cap Ltd.
CHEK
|
1.81 M | - | - | $ 9.42 M | ||
|
Aspira Women's Health
AWH
|
5.78 M | - | -6.19 % | $ 10.5 M | ||
|
Burning Rock Biotech Limited
BNR
|
372 M | $ 22.48 | -1.58 % | $ 234 M | ||
|
Bioventus
BVS
|
160 M | $ 8.45 | -7.14 % | $ 563 M | ||
|
Celcuity
CELC
|
31.7 M | $ 114.85 | -0.34 % | $ 4.53 B | ||
|
Castle Biosciences
CSTL
|
49.4 M | $ 27.23 | -2.44 % | $ 756 M | ||
|
Charles River Laboratories International
CRL
|
1.12 B | $ 175.23 | -3.37 % | $ 8.69 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
13.8 M | - | - | $ 562 M | ||
|
DermTech
DMTK
|
13.4 M | - | -11.32 % | $ 2.94 M | ||
|
Co-Diagnostics
CODX
|
5.75 M | - | - | $ 79.8 M | ||
|
Fulgent Genetics
FLGT
|
72.9 M | $ 14.59 | 2.41 % | $ 441 M | ||
|
Accelerate Diagnostics
AXDX
|
66.6 M | - | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
647 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.27 B | - | - | $ 10.7 B | ||
|
Biodesix
BDSX
|
14.3 M | $ 18.61 | 17.37 % | $ 2.41 B | ||
|
Biocept
BIOC
|
5.51 M | - | -13.05 % | $ 7.29 M | ||
|
Illumina
ILMN
|
1.55 B | $ 124.76 | -2.71 % | $ 19.8 B | ||
|
IQVIA Holdings
IQV
|
8.34 B | $ 175.33 | -1.8 % | $ 30.1 B | ||
|
BioNano Genomics
BNGO
|
37.3 M | $ 1.11 | -1.36 % | $ 1.41 M | ||
|
Heska Corporation
HSKA
|
39.6 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
8.27 M | - | -20.0 % | $ 1.06 M | ||
|
Quest Diagnostics Incorporated
DGX
|
2.28 B | $ 199.8 | -2.07 % | $ 22.2 B | ||
|
Danaher Corporation
DHR
|
6.81 B | $ 195.75 | -2.99 % | $ 140 B | ||
|
IDEXX Laboratories
IDXX
|
1.15 B | $ 607.19 | -1.9 % | $ 48.8 B | ||
|
Exact Sciences Corporation
EXAS
|
641 M | $ 103.5 | 0.17 % | $ 19.5 B | ||
|
DarioHealth Corp.
DRIO
|
12.5 M | $ 9.69 | -3.0 % | $ 275 M | ||
|
Laboratory Corporation of America Holdings
LH
|
2.82 B | $ 269.52 | -2.34 % | $ 22.4 B | ||
|
DexCom
DXCM
|
2.14 B | $ 68.5 | -3.1 % | $ 26.7 B | ||
|
QIAGEN N.V.
QGEN
|
544 M | - | - | $ 10.6 B | ||
|
ICON Public Limited Company
ICLR
|
2.8 B | $ 107.08 | -3.19 % | $ 8.83 B | ||
|
Lantheus Holdings
LNTH
|
333 M | $ 72.86 | -4.53 % | $ 4.92 B | ||
|
CareDx, Inc
CDNA
|
89.8 M | $ 17.91 | -4.48 % | $ 954 M | ||
|
Chembio Diagnostics
CEMI
|
39.3 M | - | 0.22 % | $ 16.8 M | ||
|
Mettler-Toledo International
MTD
|
1.2 B | $ 1 215.85 | -3.66 % | $ 25.1 B | ||
|
Myriad Genetics
MYGN
|
134 M | $ 5.15 | 0.29 % | $ 477 M | ||
|
NeoGenomics
NEO
|
88.3 M | $ 8.92 | -2.3 % | $ 1.14 B | ||
|
National Research Corporation
NRC
|
36.6 M | $ 14.48 | 3.13 % | $ 324 M | ||
|
Guardant Health
GH
|
303 M | $ 91.56 | -1.1 % | $ 11.5 B | ||
|
Natera
NTRA
|
310 M | $ 196.94 | -0.1 % | $ 19.4 B | ||
|
Motus GI Holdings
MOTS
|
3.27 M | - | -34.28 % | $ 263 K | ||
|
OPKO Health
OPK
|
193 M | $ 1.18 | 0.43 % | $ 819 M | ||
|
Enzo Biochem
ENZ
|
24.8 M | - | -8.98 % | $ 14.8 K |